Skip to content
  • Company
    • About us
    • Who we are
    • Management
    • Board of Directors
  • Pipeline
  • R&D
    • Research and development
    • Research platform
    • CMC
    • Publications
  • News
  • Careers
    • Values
    • Engagement & motivation
    • Meet a colleague
    • Health & Well-being
    • Open positions
  • Company
  • Who we are
  • News
  • Press kit
LinkedIn

Category: Uncategorized

March 18, 2022

Scientist for In Vivo Pharmacology

For our In Vivo Pharmacology Team, we now have an unique opening for an innovative scientist to strengthen our competencies within in vivo immune oncology.
Read more
June 4, 2020

Servier completes the acquisition of Symphogen

Symphogen becomes the antibody center of excellence within Servier
strengthening the Group’s pipeline
Read more
May 12, 2020

Symphogen to pursue COVID-19 antibody therapy in a collaboration with Aarhus University

Read more
April 3, 2020

Servier underskriver endelig aftale om at erhverve Symphogen, en førende antistof discovery virksomhed, for at styrke Serviers kapacitet inden for antistoffer samt dets forskning og udvikling

Read more
April 3, 2020

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

Read more
May 16, 2019

Symphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials

Read more
May 15, 2019

Symphogen announces new capital raise and explores strategic options

Read more
September 3, 2018

Symphogen elects new Board members to support the Company’s long-term development

Read more
1 2 3

Contact

Symphogen A/S
Pederstrupvej 93
DK-2750 Ballerup
Denmark

 

Tel +45 4526 5050
Fax +45 4526 5060

info@symphogen.com

Company

  • Company
  • Who we are
  • News
  • Press kit

 

Follow us on

Symphogen © 2023 Disclaimer - Privacy